2'-deoxyxanthosine is a synthetic nucleoside analog that has shown promising antiviral activity against various viruses, including herpes simplex virus (HSV), cytomegalovirus (CMV), and Epstein-Barr virus (EBV). It is a modified form of the naturally occurring nucleoside xanthosine, where the 2'-hydroxyl group on the ribose sugar has been removed. This modification enhances its antiviral activity by inhibiting viral DNA polymerase, an enzyme essential for viral replication. The synthesis of 2'-deoxyxanthosine typically involves chemical modification of xanthosine using a variety of methods, such as using a protecting group strategy or a one-pot reaction. 2'-deoxyxanthosine is being investigated for its potential as a therapeutic agent for viral infections, particularly for those resistant to conventional antiviral drugs. Its unique chemical structure and antiviral activity make it a promising candidate for further research and development.'
| ID Source | ID |
|---|---|
| PubMed CID | 65372 |
| SCHEMBL ID | 855722 |
| MeSH ID | M0208755 |
| Synonym |
|---|
| 9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-2,6-dione |
| xanthosine, 2'-deoxy- |
| 29049-22-7 |
| 2'-deoxyxanthosine |
| SCHEMBL855722 |
| mfcd18643182 |
| DTXSID40183285 |
| desoxyxanthosin |
| 9-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9h-purine-2,6-diol |
| 9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-9h-purine-2,6-diol |
| Class | Description |
|---|---|
| purines 2'-deoxy-D-ribonucleoside | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.97) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||